secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001837607-26-000002
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma issues corporate presentation with no new material facts
-----------------------------------------------------------------------

- Presentation dated January 2026 made available on IR website (Item 7.01).
- Reiterates ABP-450 as biosimilar to BOTOX, aiming to be first complete therapeutic alternative.
- No financial or clinical data disclosed; no guidance or milestones provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000002/0001837607-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000002/aeon-20260112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer